Diet as therapy for IBD remains hindered by knowledge gaps

ORLANDO — As patients with Crohn’s disease seek guidance on how to handle their condition, there remains a knowledge gap regarding what, if any, specific dietary regulations could become a mainstay therapy, according to a presentation at Advances in Inflammatory Bowel Disease 2019.“We don’t have enough definitive research to say that one singular diet is…

Not dead yet: The role of immunomodulators in IBD

ORLANDO — Thiopurine immunomodulators represent a potentially inexpensive and effective method for inflammatory bowel disease maintenance that can be underused as biologics became available, according to a keynote presentation from Advances in Inflammatory Bowel Disease 2019.“The challenge in our field is that all these other therapies are being marketed by drug companies and there’s no…

FDA clears first single-use, disposable duodenoscope

The FDA on Friday authorized marketing of Boston Scientific’s EXALT Model D Single-Use Duodenoscope, the first fully disposable version of the device that allows physicians to view the upper gastrointestinal tract, according to an FDA news release.The EXALT is designed for use on a single patient to avoid the need for cleaning and sterilization required…

FDA approves Xeljanz extended release tablets for ulcerative colitis

The FDA on Thursday approved Xeljanz extended release 11 mg and 22 mg tablets for the once daily treatment of adults with moderately to severely active ulcerative colitis, following an inadequate response or intolerance to previous TNF blocker therapy, according to a press release from the manufacturer.“Ulcerative colitis is a chronic inflammatory disease of the…